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2Abstract
Advanced prostate cancer is often treated with AR-antagonists which target the androgen receptor 
(AR) on which the growth of the tumour depends. Prostate cancer often develops AR-antagonist 
resistance via a plethora of mechanisms, many of which are as yet unknown, but it is thought that 
AR upregulation or AR ligand binding site mutations, may be responsible. Here we describe the 
production of cell lines based on LNCaP and VCaP, with acquired resistance to the clinically relevant 
AR-antagonists, bicalutamide and enzalutamide.
In these resistant cells, we observed, via RNA-seq, that new variants in the 3’UTR of the AR mRNA 
were detectable and that the levels were increased both with AR-antagonist treatment and with 
hormonal starvation. Around 20% of AR transcripts showed a 3kb deletion within the 6.7kb 3’UTR 
sequence. Actinomycin D and luciferase fusion studies indicated that this shorter mRNA variant was 
inherently more stable in anti-androgen resistant cell lines.
Of additional interest was that the AR UTR variant could be detected in the sera of prostate cancer 
patients in a cohort of serum samples collected from patients of Gleason grades 6-10, with an 
increasing level correlated to increasing grade.
We hypothesise that the shorter AR UTR variant is a survival adaptation to low hormone levels 
and/or AR-antagonist treatment in these cells, where a more stable mRNA may allow higher levels of 
AR expression under these conditions. 
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3Introduction.
Targeting the androgen receptor (AR) via AR-antagonist therapies is still the mainstay of advanced 
prostate cancer (PCa) treatments (1,2). AR-antagonists, such as enzalutamide, flutamide and 
bicalutamide target and competitively bind the AR, to the exclusion of testosterone (or DHT). 
Additionally AR-antagonists may mediate a misfolding of AR helix 12 and cause the AR to become 
inactive (3). In either event, the starvation of prostate cancer cells of testosterone leads to a 
reduction in tumour cell growth. Often patients undergoing AR-antagonist therapy can become 
resistant to bicalutamide via many pathways - involving AR amplification, AR ligand binding domain 
(LBD) mutations, cofactor/coregulator changes, and multidrug efflux pumps. Alternatively, in high 
grade prostate cancers, tumours may synthesise their own androgens from precursor molecules as a 
mechanism for escape from such therapies (reviewed in (4). Often PCa cells can acquire AR LBD 
mutations which can change the activity of an antagonist to an agonist, and in some cases patients 
may acquire PCa that proliferates in the presence of AR-antagonists. Such patients may respond 
better (initially) when AR-antagonists are withdrawn (5,6). In addition to all these processes, 
prostate cancer cells have been shown to produce AR splice variants – truncated versions of the AR 
with missing ligand activation domain which remain constitutively active e.g. truncated version 
known as ARv7 (7).
The LNCaP cell line represents a human PCa model derived from a patient who relapsed with 
flutamide therapy (8). The LNCaP cell line contains an AR mutation within the LDB (T877A), which 
allows a greater plethora of ligands to bind and activate the AR, including flutamide. However, the 
cell line remains sensitive to AR-antagonists such as bicalutamide and enzalutamide, but several 
publications report that prolonged treatment of the LNCaP cell line with AR-antagonists or 
prolonged hormonally starved cells can produce relevant cell lines that mimic clinically acquired AR-
antagonists resistance.
The VCaP cell line was established in 1997 from a lumbar vertebral bone metastasis from a 
metastatic lesion from a patient with hormone refractory prostate cancer. The cell line has been 
reported to have wild type AR but overexpresses it at high levels (9).
Recently, we generated bicalutamide and enzalutamide resistant clones of the LNCaP and VCaP cell 
lines, as tools for screening novel AR-antagonists compounds (10,11). The VCaPBicR/EnzR resistant 
clones showed resistance to both bicalutamide and enzalutamide – showing cytostatic effects at 
high doses. However, the LNCaPBicR cell lines showed a proliferative response to bicalutamide, whilst 
LNCaP/EnzR cells showed a more cytostatic effect at high doses.
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4In an attempt to discover the potential mechanism of AR-antagonist resistance and to discover if any 
novel AR variants were being expressed or if novel LBD mutations were present, we subjected 
LNCaPBicR cells to RNA-seq. Here we discuss the finding that although no new coding variant or 
mutations were seen, we did discover an increase in an AR variant, in the 3’UTR region. Here we 
investigate how the variant conveys extra stability to the AR mRNA transcript and may be in part 
responsible for increased AR mRNA and protein expression in response to AR-antagonist mediated 
hormone starvation.
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LNCaP cells were maintained at 37oC, 5% CO2 in RPMI medium with 10% foetal bovine serum (First 
Link Ltd, Brierley Hill, U.K.).  PC3, VCaP and Du145 cells were maintained in DMEM medium (Sigma) 
with 10% foetal bovine serum (First Link UK,). All media was supplemented with 2mM L-glutamine, 
100units/ml penicillin, 100mg/ml streptomycin (Sigma). For hormone depletion experiments, 72 
hours before androgen exposure, medium was replaced with ‘starvation medium’ consisting of 
phenol red-free RPMI (or DMEM) medium, supplemented with 5% charcoal-stripped foetal bovine 
serum (First Link UK). All cells were obtained from the ATCC cell bank in 2017, and kept in liquid N2 in 
aliquots thereafter. All cells were used within 10 passages of the original stock. RNA-seq of the 
samples also verified these cell lines in terms of oncogenes and documented mutations.
Treatments
All AR-antagonist compounds were obtained from Sigma, and made up in DMSO stock at 10mM and 
kept at -20C.  Actinomycin-D was made up in DMSO at 100g/ml, and kept at -20C. Working solution 
was 1g/ml.
Generation of bicalutamide resistant cells
LNCaP and VCaP cells were grown in increasing doses of bicalutamide or enzalutamide (0-30M) for 
up to 6 weeks at which time cells began to show proliferation. Resistant cell lines were expanded 
from these and resistant clones grew stably in medium containing 20M AR-antagonist.   
MTT Assays
The MTT assay was used as a cell viability assay for the all the cell lines listed using the AR-antagonist 
compounds.  Briefly, cells (5 × 104 cells/ml) were seeded into 96-well plates (200ul/well), allowed to 
attach and grow for 24hr and subsequently treated with varying concentrations of AR-antagonists 
(0–100 μM) for 96 hours. Optimal seeding densities were premeasured for linear growth over the 
96hours. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5mg/ml in PBS) was 
added to a final concentration of 0.5mg/ml for 4 h at 37oC. After four hours, purple formazan 
crystals, formed by mitochondrial reduction of MTT, were solubilized in acidified isopropanol 
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6(200μl/well) and the absorbance was read at 570 nm after 10 min incubation.  Percent inhibition of 
viability was calculated as a % of untreated control and the cytotoxicity / cell growth inhibition was 
expressed as IC50.
AR 3’UTR Transfection and Luciferase Assays
AR UTR reporters were a kind gift from Dr Paivi Ostling (Science for Life Laboratory, Sweden). Cells 
were transfected with AR-UTR reporter vectors (12), and a constitutive expression renilla vector 
(pGL4.75 Promega) alongside using Lipofectamine 3000 (Life Technologies). 24 hours after 
transfection cells were washed and lysed in reporter lysis buffer (Promega). Lysate was mixed with 
D-luciferin substrate (Promega), and then with renilla substrate (Promega). Light emission measured 
using the Promega Glomax multi luminometer. Luciferase activity was normalised to renilla 
expression. 
RNA extraction and RT-PCR
Total RNA samples were prepared using Trizol reagent (Sigma) and converted to cDNA using the 
GoScript™ Reverse Transcription System (Promega).
Q-PCR
Reactions were performed in triplicate on cDNA samples in 96-well optical plates on an ABI Prism 
StepOne System (ThermoFisher, U.K.). Reactions consisted of 2 μl cDNA, 7 μl PCR-grade water, 10 μl 
2× TaqMan Universal PCR Master Mix (Applied Biosystems), 1 μl Taqman specific assay probes 
(Applied Biosystems) for PSA, and RPL19 or SYBR green primers for AR, AR-UTR (variants), -actin 
and GAPDH. Parameters were: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 sec and 60°C 
for 1 min. Data was recorded using Sequence Detector Software (SDS version 2.3; PE Applied 
Biosystems). Levels were normalised to GAPDH, -actin and RPL19.
RNA-seq analysis
PolyA mRNA was isolated from total RNA using the Dynabeads mRNA DIRECT Kit (Life Technologies, 
UK) and verified using a Bioanalyser-2100 (Agilent). RNA fragment libraries (150-200bp) were 
generated using the Ion Total RNA-Seq kit (Life Technologies) and ligated to adapters for cDNA 
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7synthesis. cDNA was then amplified using IonXpress RNA-seq  barcoded primers (5’) and quantified 
with a Qubit assay (Life Technologies).
cDNA libraries were clonally amplified by emulsion PCR on Ion Sphere Particles (ISP’s) using Ion PI 
template OT2 200 kit (Life technologies, USA) on an Ion OneTouch2 system (Life technologies) as per 
manufacturer’s instructions. The template positive ISP’s were recovered and enriched to remove 
non-template ISP’s on Ion One Touch ES (Life technologies). The ISPs were processed using the Ion 
Proton 200 sequencing kit and loaded onto a P1 chip and sequenced on an Ion Proton (Life 
technologies) using default parameters (single-end, forward sequencing). Base calling, adaptor 
trimming, barcode deconvolution and alignment was performed on Torrent Suite version 3.6 (Life 
technologies) using the STAR RNA-seq aligner plugin. The Partek Genomic Suite 6.6 software was 
used for data analysis. The RPKM normalization method for RNA-seq 45 was used followed by a 1-
way Anova test for gene differential expression (from n=4 samples per group). For transcript 
analysis, we utilised the RNA STAR aligner (or HISAT2 v2.1.0) followed by the Bowtie and TopHat 
splice aware mapping software (UCSC Galaxy). Finally, Cufflinks (version 2.2.1) and DESeq2 (version 
1.12.4 running on R version 3.3.0) were used to build transcript information and visualised in IGV 
(Integrative Genomics Viewer) software (Broad Institute, University of California, USA).
For online GEO dataset analysis, we used an SRA download tool (UCSC Galaxy), followed by 
alignment as listed above, and analysis via StringTie (v1.3.6).
Serum collection
Clinical samples were obtained from the Wales Cancer Bank (WCB) in accordance with their ethics 
and patient consent, following application and approval (WCB application number 15/009). In total 
124 samples of serum were used from patients with confirmed prostate cancer. The median patient 
age was 65 years and the median follow up period was 4 years. Patient serum was collected at the 
point of first diagnosis based on pathological Gleason grade from biopsy, prior to any treatment. No 
TNM data was available. In addition we collected serum samples from normal healthy male 
volunteers, with an age range of 20-55 years (ethics number SMREG ref:13.69). 50l of serum was 
used and RNA was extracted using 150l of Trizol LS. 
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8Results
AR mRNA transcript and protein expression are increased with acquired AR-antagonist resistance.
We set out to analyse and study the mechanism of action of acquired AR-antagonists resistance in 
prostate cancer cell models. The baseline sensitivity of LNCaP and VCaP cells to bicalutamide and 
enzalutamide was measured using the MTT assay for cell viability. Treating cells for 96hours in 
increasing doses of bicalutamide showed an IC50 of 3M for LNCaP cells and 2.5M for VCaP cells. 
Enzalutamide gave IC50 values of 2 and 2.3M respectively. After continual culture and growth in 
20M bicalutamide or enzalutamide for 6 weeks approx. these cells began to grow and proliferate as 
normal, and cell lines were expanded – henceforth labelled LNCaPBicR/EnzR and VCaPBicR/EnzR. A further 
MTT analysis for the IC50 revealed that LNCaPBicR cells now proliferated in bicalutamide reaching 
maximal growth at approx. 20M (see figures 1A). Enzalutamide still showed some activity in 
LNCaPEnzR cells, but the IC50 was now 15M (approx.) (see figure 1A).  In VCaP resistant cell lines, 
both bicalutamide and enzalutamide failed to give an IC50 dose, but no dose-responsive proliferation 
was observed (see figure 1B). 
Analysis of AR and prostate specific antigen (PSA) expression in these cell lines confirmed that VCaP 
and LNCaP were indeed AR+ve when compared to PC3 and Du145 – cell lines known to be androgen 
receptor negative (see figure 1C). When we compared parental and resistant cell lines we observed 
that AR expression was increased 2-fold in the resistant cell lines (see figure 1D) – although the 
levels of AR transcripts was much higher in VCaP cells (x100 fold). We PCR-amplified and sequenced 
the AR LBD domain from these cell lines and did not observe any AR mutations apart from T877A, 
carried by the LNCaP cell line. Protein levels for AR also increased in the resistant LNCaP cell lines by 
1.3 fold (see figure 1E).
AR transcripts differ in the 3’UTR region in LNCaP with acquired bicalutamide resistance.
We then analysed the changes in gene expression in the LNCaP vs LNCaPBicR cell lines by RNA-seq. 
When analysing the AR transcripts we did not observe any AR coding region splice variants e.g. ARv7, 
however we did observe that the 3’UTR region of some AR transcripts showed an anomaly. Data is 
available at NCBI BioProjects accession PRJNA578661 (ncbi.nlm.nih.gov).
In the parental LNCaP cells, three distinct AR transcripts were identified. Two were complete 
matches of known transcripts (according to RefGene gene model) and one was a potentially novel 
transcript. However, in the LNCaPBicR cell line five distinct AR transcripts were identified, two of 
which were complete matches of known transcripts and three were potentially novel transcripts. 
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9Figure 2A showed the analysis schematic from IGV software, showing the Cuffmerge data output. 
Figure 2B showed a detailed schematic of the 3’UTR region of AR. The novel transcripts had a 
missing 3kb region in the UTR sequence, from bases 1795-4832 of the UTR sequence.  The 
coordinates are counted from +1 after the stop site in the AR mRNA sequence (Refseq: 
NM_000044), see supplemental data. The missing region corresponds to ChrX: position 66,945,4780 
- 66,948,515 (GRCh37/hg19 assembly). Additionally, we saw another transcript with a slightly larger 
missing region from bases 1795-4961 (see figure 2B). The novel transcript we will henceforth 
referred to as AR3.7kb-UTR, as opposed to AR6.7kbUTR, for the normal full length AR transcript.
3’UTR deletion correlates with splice sites.
From the IGV analysis, reads mapping to the 3’UTR spanned the missing 3kb region, indicating that a 
splicing or editing event was responsible. Therefore, we analysed the 3’UTR region of the AR mRNA 
via various online resources for splice site analysis. Utilising Spliceport 
(http://spliceport.cbcb.umd.edu/SplicingAnalyser2.html), NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2/) and  RegRNA 
(http://regrna2.mbc.nctu.edu.tw/detection.html) analysis software we found that the bases 1795 
and 4832 (and 4961) were predicted splice donor and acceptor regions respectively with the highest 
confidence value or free energy score. Figure 2B shows a schematic of the base numbers and 
deleted region of the 3’UTR of AR. Figure 2C shows the output from SplicePort for both donor and 
acceptor predicted sites. We did not detect the novel spliced region in genomic DNA from LNCaP 
cells, again indicating a post transcriptional modification. 
Spliced AR 3’UTR variant increases due to hormonal starvation or AR-antagonist treatment.
Utilising primers specific for various regions across the UTR (see figure 3A), we analysed if the 
shorter UTR transcript could be detected by PCR. Utilising primers C&D for the long UTR variant and 
B&E for the shorter UTR variant (see figure 3A), we carried out qPCR on the cell lines. The C&D 
primer set amplify a region present only in the complete full length AR 3’UTR. The B&E primer set 
only amplify the AR 3’UTR across a small region (200bp) of the shorter spliced variant. 
Parental VCaP cells showed a 15-fold increase over LNCaP in AR-UTR expression (see figure 3B). 
However, interestingly, parental VCaP cells also showed a 4-fold increase in the novel shorter UTR 
variant than LNCaP cells (see figure 3B). Further, we then analysed the levels of the normal UTR 
(primers C&D), and UTR variant (AR3.7kb-UTR - primers B&E) in the resistant cell lines compared to the 
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parental cell lines. This also showed increased expression of the shorter variant in all resistant cell 
lines (see figure 3C), compared to their parental cells.
We then went on to study if the increase in levels of the 3’UTR variants in the parental cells changed 
rapidly following either hormone starvation or AR-antagonist treatment, or whether the AR variant 
was a product of a longer term adaptation. When LNCaP cells were hormonally starved for 72hours 
we saw a strong reduction in the levels of the androgen-inducible gene, PSA, as expected (see figure 
3D upper panel). Also, as expected, when starved, LNCaP cells upregulated their levels of AR mRNA, 
therefore, the AR coding region and the normal UTR levels showed an increase of around 6-8 fold 
(see supplemental figure 1.). However, the shorter UTR variant could be detected at approx. 20 
times the level found in parental cells (see figure 3D lower panel). Hormonal starvation for 96 hours 
also increased the level of AR protein by 2 fold (see figure 3E). When the parental LNCaP cells were 
treated with 20M bicalutamide for up to six days, we observed a decrease in PSA, as expected, but 
an increase in shorter UTR variant, which increased over time (see figure 3F). 
The spliced AR 3’UTR variant is more stable in cells with acquired AR-antagonist resistance.
To monitor if the shorter AR UTR variant conferred an advantage to the stability of the AR mRNA 
strand we treated parental and AR-antagonist resistant cells with actinomycin-D to halt RNA 
transcription. Total RNA was then extracted from cells at various timepoints. In LNCaP cells 
actinomycin-D significantly reduced expression of all transcripts over 24 hours. The levels of GAPDH, 
-actin and AR (coding region), AR6.7kb-UTR did not show any significant differences between the cell 
lines. However, in the resistant cells the residual levels of AR3.7kb-UTR transcript showed an increased 
level compared to the parental cell lines at 10 hours (see figure 4A), but was similarly reduced at 24 
hours. Similar results were seen in VCaP cells, but to a reduced level (see supplemental figure 2).
We then tested the relative stability of different regions of the AR UTR using luciferase reporter 
constructs. Using seven AR UTR overlapping constructs (12) of approximately 1kb each, were 
transfected into LNCaP or LNCaPBicR cells for 24hours, and measured luciferase activity over a 
constitutively expressed renilla luciferase. Regions 1, 2, 3, 6 and 7 showed increased stability in the 
LNCaPBicR cells, but regions 4 and 5 which lie within the spliced region of the UTR showed a reduced 
stability, (see figure 4B). 
The 3’UTR variant is present in online GEO datasets including LNCaP-abl cells, immortalised 
prostate epithelial cells and in patient samples prior to AR-antagonist  therapy.
Page 10 of 33Accepted Manuscript published as EC-19-0340.R1. Accepted for publication: 28-Nov-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 12/02/2019 05:37:41AM
via free access
11
Both the LNCaP and VCaP cell lines showed low levels of the AR UTR variant before the treatment 
with AR-antagonist, but these cell lines represented cells taken from patients with advanced 
prostate cancer who had been treated with various endocrine therapies e.g. flutamide (and/or other 
treatments). We, therefore, analysed several online data sets from the GEO database for the 
presence of the 3’UTR variant. In all studies analysed, the 3’UTR missing region was seen at some 
levels, albeit very low. Using online data from Olsen et al, GSE71797 (13), in hTert immortalised 
benign prostate epithelial cells we detected the presence of the transcript in some samples but not 
all (see supplemental figure 3A). Additionally, using data from Rajan et al, GSE48403 (14) we again 
found the presence of the shorter AR UTR variant. The 3’UTR variant was seen to be elevated in 
prostate cancer patients post AR-antagonists therapy, but due to low sample numbers (n=6) the 
data did not reach significance. Data is given in supplemental figure 3B. 
The AR UTR was also detected and was increased (p=0.03) in a study by Knuuttila et al, (GSE95413) 
in orthotopically grown castration resistant VCaP xenografts treated with enzalutamide (see 
supplemental figure 4A). In a study by Shah et al, (GSE81796) using C4-2 cells (CRPC) the AR3.7kb-UTR 
was present and was increased by enzalutamide treatment (see supplemental figure 4B). And in a 
study by Coleman et al, (GSE87153), the AR3.7kb-UTR was seen to be increased in the LNCaP-derived 
MR49F cell line – grown in castrated mice and enzalutamide treated (see supplemental figure 4C). 
The variant was present in V16D cell line (LNCaP derived, castration resistant), but was not further 
elevated with enzalutamide. This missing region in the AR UTR was also observed in a study by Kohli 
et al, (GSE70380), in samples derived from metastatic deposits from a patient with disease 
progression whilst on androgen deprivation therapy (see supplemental figure 4D).
The LNCaP-abl cell line represents LNCaP cells grown in androgen-depleted medium for over 80 
passages, and mimics castrate-resistant prostate cancer. A GEO dataset (GSE114708) utilising the 
LNCaP-abl cell line (15) showed the presence of the AR3.7kb-UTR variant, see supplemental figure 4E. 
The AR 3’UTR variant is detectable in prostate cancer patient serum.
Since prostate cancer cells and/or prostate cancer cellular DNA/RNA may circulate in the serum of 
prostate cancer patients, we evaluated whether the novel variant could be detected in their sera. 
We extracted total RNA from prostate cancer patients’ sera, collected from the Wales Cancer Bank 
(n=124) ranging from Gleason grade 6-10, with associated PSA values. Additionally, serum was 
collected from apparently healthy male volunteers (n=8). These were determined by clinical 
pathologists at the Heath Hospital Cardiff, UK. RNA was isolated and qPCR performed, for AR (coding 
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region), AR6.7kb-UTR (primers C&D), and for the AR3.7kb-UTR (primers B&E), along with GAPDH, -actin 
and RPL19. Patient data and numbers can be seen in supplemental Table 1.
When analysed according to Gleason grade, we found a positive correlation with PSA as expected, 
but additionally we saw a positive correlation with increasing grade and the quantity of AR3.7kb-UTR 
variant in the serum (see figure 5A&B), and statistically significant differences between Gleason 
grade 6 and 9 (p= <0.05).  No correlation was seen between the levels of AR coding region and 
Gleason grade, however, a positive correlation with grade was also seen for the full length AR6.7kb-UTR, 
see figures 5C&D.
When analysed for patient follow up and survival, both PSA and AR3.7kb-UTR was elevated in the 
deceased group, (p = <0.05 & p= <0.02) respectively. However, due to very small numbers we treat 
these results with caution. AR6.7kb-UTR and AR coding region levels did not correlate with survival. 
Discussion
During prostate cancer treatment AR-antagonists are often used to reduce tumour growth and 
prolong life. Initially, AR-antagonists are effective but frequently these become ineffective and 
patients relapse with prostate cancer which is resistant to further AR-antagonist treatment. 
Additionally, AR-antagonists may bind and activate the AR causing a stimulatory effect. In instances 
such as these, prostate cancer patients may benefit from AR-antagonist withdrawal. We set out to 
investigate the mechanism behind acquired resistance to AR-antagonist in prostate cancer cells by 
generating cells resistant to the two most clinically relevant AR-antagonists, namely bicalutamide 
and enzalutamide.  
For LNCaP and VCaP cells, the acquisition of AR-antagonist resistance was established at 20M, 
whereas at 30M no growth or very slow cell growth was observed. However, when these resistant 
cells were then exposed to a range of drug concentrations 0-100M we saw different effects 
dependent on the drug and cell line. VCaP showed resistance to enzalutamide and bicalutamide with 
no apparent cell killing up to 50-100mM. LNCaP showed similar properties with enzalutamide. 
However, LNCaP cells showed a proliferation response with bicalutamide, peaking at 20M. This 
effect is probably due to the steric fit of bicalutamide in the mutant AR ligand binding domain 
(T877A) carried by the LNCaP cell line causing a more promiscuous ligand binding. This may also 
mimic the clinical situation where patients sometimes respond better – albeit briefly – when AR-
antagonists are removed. 
Page 12 of 33Accepted Manuscript published as EC-19-0340.R1. Accepted for publication: 28-Nov-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 12/02/2019 05:37:41AM
via free access
13
When analysing AR mRNA levels in these resistant cells, we found expression to be higher at the 
mRNA and protein level. The increased expression of AR has been previously reported in cells either 
starved of hormone or inhibited by AR-antagonists. VCaP cells show a much higher baseline 
expression of AR and has been reported previously, but even in these cells AR expression was still 
higher in the resistant clones.
When we analysed the AR by RNA-seq we did not discover any new or additional mutations in any of 
these cells lines, neither did we find any novel AR coding variants e.g. ARv7. However, the RNA-seq 
and associated Cufflinks analysis did reveal an increase in transcript number and variation. Three 
isoforms were seen in parental LNCaP cells. The first being AR variant 1 (refseq: NM_000044) and 
the other being AR variant 2 (refseq: NM_001011546), which are previously identified variants. 
Variant 2, has an alternate start codon in the 5' region, with an encoded isoform (variant 2) which 
has a distinct and shorter N-terminus than isoform 1. However, even in these parental cells another 
isoform was seen with a shorter 5’ UTR sequence and a missing 3kb region from the 3’UTR. In the 
LNCaPBicR cell line five transcripts were seen - the three variants seen previously in the parental cell 
lines and two more variants which were the AR variant 2 but with a missing 3kb region in the 3’UTR 
and an alternate variant 1 with a missing slightly larger 3.1kb region. 
Since RNAseq reads spanned this area, and were aligned and mapped as genuine reads to the AR 
gene, we had to surmise that the missing 3 – 3.1kb were caused by ‘splicing’ or ‘stitching’ events. 
Splice site analysis matched up precisely with donor and acceptor sites on several web based 
platforms. The novel variant region could not be PCR amplified from genomic DNA, also indicating a 
post transcriptional splicing event.
Although AR coding and AR UTR levels were elevated in AR-antagonists resistant cells, PCR analysis 
confirmed that the missing UTR variant elevated in increasing amounts, indicating that additional AR 
transcripts with the missing region were present in these cells. Even though the high levels of AR3.7kb-
UTR were seen in fully resistant cells, we saw that the adaptive response was rapid, being detectable 
after 24hours of AR-antagonist treatment and after 6 days of hormone starvation. 
Additionally, to test whether the AR ‘splicing’ event was unique to AR pathway inhibition or was a 
more general stress response, we subjected LNCaP cells to a variety of cellular stresses including 
hypoxia (mimicked by CoCl2), DNA damaging stress (by doxorubicin, cisplatin and paclitaxel) and 
environmental stress such as oxygen radicals (by H2O2) and extracellular low pH.  We observed that 
both AR variants (3.7 & 6.7kb UTRs) were upregulated in response to environmental stresses e.g. 
oxygen or pH, but were not significantly altered in response to DNA damaging agents ( see 
supplemental figure 5). All stress treatments reduced cellular proliferation as measured by the 
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expression of the MCM5 DNA replication gene. Oxygen level changes and low pH are significant 
factors within tumours, and may together with AR antagonism, play a role in prostate cancer. The 
‘splicing events observed here may part of a more generic stress-induced novel or aberrant splicing 
pathway. 
We hypothesised that the AR variant was a result of an adaptive response to lack of androgen where 
the AR mRNA levels increased, and as is the case for alternative ‘splicing’, the mRNA strand itself 
may have an altered stability. Splicing of the coding region of the AR has been studied extensively, 
but UTR variants have not (7,16). For example if the shorter UTR variant was more stable, then this 
would give the AR mRNA a longer half-life, and a higher expression which would give cells a survival 
advantage. We tested this hypothesis by using actinomycin-D to stop cellular transcription of all 
transcripts and measured the halflife of the remaining transcripts. 24hour of actinomycin treatment 
reduced all transcripts measured including GAPDH, -actin, AR6.7kb-UTR and AR3.7kb-UTR. However the 
AR3.7kb-UTR showed a higher level, and reduced rate of degradation. Additional analysis using AR UTR 
reporters fused to luciferase showed that two regions (4 & 5) showed a reduced activity / stability in 
the LNCaPBicR cell line, whereas all other regions showed an increased activity. Regions 4 & 5 were in 
the missing 3kb region of the novel transcripts. Taken together, we hypothesise that in the 
adaptation to AR-antagonist resistance the 3kb RNA region missing in AR3.7kb-UTR may be detrimental 
for stability of the mRNA strand and may be spliced out to increase stability as a survival advantage 
for the cancer cells. Although a hypothetical explanation at this stage, we would suggest that this 
splicing or stitching of the UTR sequence may be a mechanism to avoid or circumvent microRNA or 
noncoding RNA downregulation of the AR strand. MiR analysis software indicated at least 40 
potential binding sites in the 3kb were missing from the AR3.7kb-UTR mRNA strand. For example, if 
microRNA upregulation was a part of the adaptive AR-antagonist resistance response, then the 
shortening of the UTR would lessen the chance of AR itself being targeted by these miRs. Studies by 
Ostling et al, 2011, found several active microRNAs which target the 3’UTR of AR in the deleted 
region e.g. miR-185, miR-371-3p and miR-135. MiR-185 has been shown to downregulate AR levels 
and is itself downregulated in prostate cancer samples, Chunyan et al, 2015; Qu et al 2013.
Splicing dysregulation has been hypothesised to be associated with cancer and survival mechanisms 
e.g. in PI3kinase/Akt pathways (17,18). 3’UTR splicing events have been found for other genes and is 
associated with transcript stability (19-22). Often cells utilise alternative cleavage and 
polyadenylation sites to reduce UTR length and increase mRNA stability (Mayr et al, 2009), but in the 
enzalutamide resistant cells studied here, although the UTR length is indeed shortened the terminal 
polyadenylation site is unchanged. This would again imply a novel mRNA ‘splicing’ and editing event 
has occurred for the AR. 
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The AR3.7kb-UTR variant was present in the parental LNCaP and VCaP cell lines, but was more 
prominent in the resistant cells. We then looked at several online GEO dataset to determine if the 
variant was common or cancer specific. In immortalised (hTERT) prostate epithelial cells and in 
epithelial cells undergoing mesenchymal transition, the variant was present but at very low levels, 
however, in cancer samples and cancer samples from AR-antagonist resistant refractory patients we 
found the levels to be higher, with even higher levels in refractory patients – although not significant 
due to low numbers (p=0.3). Therefore, the variant may be a naturally occurring transcript present 
at low levels, which is stabilised or upregulated at times of cellular stress. 
Patients’ plasma and serum have been used in the other studies to measure circulating AR levels 
(23,24). In prostate cancer patients’ sera, we tested whether the AR variant could be detected, as 
well as the normal AR UTR and the AR coding region. Additionally, we compared the patient Gleason 
grade and PSA levels as indicators of disease. All three AR regions were detectable but it was only 
the UTR regions that correlated with grade across the patients’ samples, and showed significant 
differences between grades 6 and 9 & 10. Additionally, both PSA and AR3.7kb-UTR showed a 
significantly higher level in those patients who had died of prostate cancer in the interim follow up. 
This was a surprising finding as numbers were low, but no significant correlation could be seen 
between PSA and AR3.7kb-UTR. To our knowledge, these patients were naive to any endocrine 
treatment protocols, therefore taken together with the online GEO datasets, the appearance of the 
variant is not caused by AR-antagonist treatments but is upregulated by it. Unfortunately, follow up 
data on how patients went on to respond to AR-antagonist therapies were unavailable at the time of 
this study. Previously, the detection of AR-v7 in whole blood did not predict effectiveness of AR-
antagonist for castration-resistant prostate cancer (24).
In conclusion, we report that an AR3.7kb-UTR variant levels increase in prostate cancer cells which have 
acquired resistance to bicalutamide / enzalutamide or indeed shorter term hormonal starvation. This 
variant is present at low levels in most cells studied, but the levels are increased in the resistant 
cells, and the novel variant may be associated with a splicing event. We hypothesise that this variant 
increases AR mRNA stability, thus may increase protein levels and may provide prostate cancer cells 
a survival advantage.
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Figure 1. AR transcript expression is increased with acquired AR-antagonists  resistance.
A, MTT cytotoxicity assays of LNCaP, LNCaPBicR and LNCaPEnzR cells treated with increasing 
concentrations of either bicalutamide (left hand side) and enzalutamide (right hand side), at 0-
100M for 96hours. B, MTT cytotoxicity assays of VCaP, VCaPBicR and VCaPEnzR cells treated with 
increasing concentrations of either bicalutamide (left hand side) and enzalutamide (right hand side), 
at 0-100M for 96hours. C, qPCR analysis of AR and PSA expression levels in four prostate cancer cell 
lines, as indicated. D, qPCR analysis of AR expression levels in parental and resistant prostate cancer 
cell lines as indicated. Data represents the mean and standard error from three independent 
replicates. Data is normalised to housekeeping genes GAPDH, RPL19 and -actin. E, Western blot for 
AR levels from LNCaP and LNCaP/Bic/Enz cells, normalised to -actin. Statistical analysis * (p =0.05) ** 
(p = 0.01) from a t-test.
Figure 2. AR transcripts differ in the 3’UTR region with acquired AR-antagonists resistance.
A, IGV screenshot of the AR transcripts detected in RNAseq samples from LNCaP and LNCaPBicR cells. 
Upper panel indicated the genomic location of the AR intron and exon regions as well as the 5’ and 
3’ UTR regions. B, Schematic diagram of the full 3’ UTR region of AR (6.7kb), with the missing 3kb 
region indicated as a hatched box, and missing 3.1kb regions (lighter hatched box). The numbers 
represent the bases in the UTR region at which the missing region are spanned by RNAseq reads. C, 
Analysis results from the Spliceport splice analysis online tool. Left hand side indicates bases scoring 
highly as splice donor regions and right hand side shows bases scoring highly as splice acceptor 
regions.
Figure 3. AR 3’UTR variant increases due to hormonal starvation or AR-antagonists  treatment.
A, Schematic diagram indicating the binding location of qPCR primer sets used for detecting either a 
portion of the 6.7kb 3’UTR of AR (upper panel) or the novel shorter AR 3kb transcript (lower panel). 
Numbers represent base locations in the 3’UTR. B, qPCR analysis of the AR UTR utilising the 
indicated primers sets in parental LNCaP or VCaP cells. C, qPCR analysis of AR6.7kb-UTR variant and 
AR3.7kb-UTR variant in parental and resistant LNCaP and VCaP clones. D, qPCR analysis of PSA (upper 
panel) and AR3.7kb-UTR (lower panel) in LNCaP cells grown in starvation medium for 72hours. E, 
Western blot for AR protein levels in hormonally starved LNCaP cells for 0-96 hours. Normalised to 
-actin, with associated densitometry underneath. F, qPCR analysis of PSA (upper panel) and AR3.7kb-
UTR variant (lower panel) in LNCaP cells treated with bicalutamide (10M) for 6 days. Data represents 
the mean and standard error from three independent replicates. Data is normalised to housekeeping 
genes GAPDH, RPL19 and -actin. Statistical analysis * (p =0.05) ** (p = 0.01) from a t-test.
Figure 4. Spliced AR 3’UTR variant is more stable in cells with acquired AR-antagonists resistance.
A, qPCR analysis of GAPDH, -actin, AR3.7kb-UTR variant and AR6.7kb-UTR variant from LNCaP or LNCaPBicR 
cells treated with actinomycin D (1g/ml) for 0 – 24hours. Data represents the mean and standard 
error from three independent replicates. Data is normalised to housekeeping genes GAPDH, RPL19 
and -actin, and then expressed as a % of expression at time 0. B, Upper panel - schematic diagram 
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of the location of the Luciferase-AR UTR reporter fusion constructs in the 6.7kb region. Lower panel 
– luciferase activity of the reporter constructs in LNCaP or LNCaPBicR cells transfected with the 
firefly luciferase reporters and a constitutive renilla luciferase reporter. Data is expressed as firefly 
luciferase / renilla luciferase. Statistical analysis * (p =0.05) ** (p = 0.01) from a t-test.
Figure 5. Spliced AR 3’UTR variant is detectable in prostate cancer patient serum.
A, Serum PSA measurements from the prostate cancer patient cohort - data from the Wales Cancer 
Bank. Data is separated according to Gleason grade 6-10, assigned to each patient at pathological 
diagnosis. B, qPCR analysis of the AR3.7kb-UTR variant from RNA extracted from patient serum samples. 
C, qPCR analysis of the AR coding region from RNA extracted from patient serum samples.  D, qPCR 
analysis of the AR6.7kb-UTR variant from RNA extracted from patient serum samples. Data represents 
the mean and standard error from three independent measurements. Data is normalised to 
housekeeping genes GAPDH, RPL19 and -actin. Statistical analysis * (p =0.05) ** (p = 0.01) from a 1-
way Anova test (Kruskal Wallace test).
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LNCaP IC50 = 3M
LNCaP/BicR IC50 = NA
LNCaP IC50 = 2M
LNCaP/EnzR IC50 = 15M
VCaP IC50 = 2.5M
VCaP/BicR IC50 = NA
VCaP IC50 = 2.3M
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Q-PCR analysis of A, AR UTR and B, AR coding region in LNCaP cells grown in stavation medium for 72 hours. 
Data represents the mean and standard error from three independent replicates. 
Data is normalised to housekeeping genes GAPDH, RPL19 and b-actin. 
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Q-PCR analysis of GAPDH, AR3.7kb-UTR and AR6.7kb-UTR from VCaP or VCaPBicR cells treated with actinomycin-D
(1ug/ml) for 0-24hours. Data represents the mean and SE from three replicates. Data is normalised to the
housekeeping genes GAPDH, RPL19, and b-actin, and then expressed as a % expression at time = 0.
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p = 0.4p = 0.03
*
p = 0.1
A, Boxplot showing the analysis of the AR DUTR variant (in RPKM) from VCaP xenografts treated with
enzalutamide. B, Graph showing analysis results of AR DUTR (RPKM) from C4-2 cells treated with
enzalutamide. C, Graph showing analysis results of AR DUTR (RPKM) from the MR49F cell line – grown
in castrated mice and enzalutamide treated. D, Screenshot from Cuffmerge data analysis from
metastatic deposits of a patients with disease progression. E, Screenshot from Cuffmerge data analysis
from LNCaP-abl cells.
E. GSE114708
Page 29 of 33 Accepted Manuscript published as EC-19-0340.R1. Accepted for publication: 28-Nov-2019























































Q-PCR analysis of LNCaP cells treated with various conditions including hypoxia mimic CoCl2
(100mM), HCl (10mM), Paclitaxel (1nM), Doxorubicin (1mM), Cisplatin (3mM), H2O2 (0.1mM) for 24
hours. Data is normalised to GAPDH, b-actin and RPL19.
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Text indicated the full UTR sequence of AR starting immediately after the STOP codon (not shown). Yellow 
highlighted text indicates the missing 3kb region found in the AR3.7kn-UTR variant. Red highlighted text 
indicates the location of the primers for q-PCR (in the order of A, B, C, D, E, F.  
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